Spacelab experiments on space motion sickness.
Recent research results from ground and flight experiments on motion sickness and space sickness conducted by the Man Vehicle Laboratory are reviewed.  New tools developed include a mathematical model for motion sickness, a method for quantitative measurements of skin pallor and blush in ambulatory subjects, and a magnitude estimation technique for ratio scaling of nausea or discomfort.  These have been used to experimentally study the time course of skin pallor and subjective symptoms in laboratory motion sickness.  In prolonged sickness, subjects become hypersensitive to nauseogenic stimuli.  Results of a Spacelab-1 flight experiment are described in which four observers documented the stimulus factors for and the symptoms/signs of space sickness.  The clinical character of space sickness differs somewhat from acute laboratory motion sickness.   However SL-1 findings support the view that space sickness is fundamentally a motion sickness.  Symptoms were subjectively alleviated by head movement restriction, maintenance of a familiar orientation with respect to the visual environment, and wedging between or strapping onto surfaces which provided broad contact cues confirming the absence of body motion.
Oman
C M
CM
Department of Aeronautics and Astronautics, Massachusetts Institute of Technology, Cambridge 02139, USA.
D000222:Adaptation, Physiological / Q000502:physiology; D018663:Adrenergic Agents / Q000627:therapeutic use; D000932:Antiemetics / Q000627:therapeutic use; D003913:Dextroamphetamine / Q000627:therapeutic use; D004198:Disease Susceptibility; D004809:Ephedrine / Q000627:therapeutic use; D018495:Fluid Shifts / Q000502:physiology; D006801:Humans; D008433:Mathematics; D008959:Models, Neurological; D008991:Monitoring, Physiologic; D010167:Pallor / Q000503:physiopathology; D011398:Promethazine / Q000627:therapeutic use; D012601:Scopolamine / Q000627:therapeutic use; D012684:Sensory Thresholds / Q000502:physiology*; D013026:Space Flight; D018489:Space Motion Sickness / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy; D014893:Weightlessness / Q000009:adverse effects*
D018663:Adrenergic Agents; D000932:Antiemetics; D012601:Scopolamine; D011398:Promethazine; D004809:Ephedrine; D003913:Dextroamphetamine